Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy.

Baert F, Drobne D, Gils A, Vande Casteele N, Hauenstein S, Singh S, Lockton S, Rutgeerts P, Vermeire S.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1474-81.e2; quiz e91. doi: 10.1016/j.cgh.2014.01.033. Epub 2014 Jan 29.

PMID:
24486408
2.

Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, Ungar B, Eliakim R, Chowers Y, Shamir R, Fraser G, Dotan I, Ben-Horin S.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):522-530.e2. doi: 10.1016/j.cgh.2014.07.029. Epub 2014 Jul 25.

PMID:
25066837
3.

Withdrawal of immunomodulators after co-treatment does not reduce trough level of infliximab in patients with Crohn's disease.

Drobne D, Bossuyt P, Breynaert C, Cattaert T, Vande Casteele N, Compernolle G, Jürgens M, Ferrante M, Ballet V, Wollants WJ, Cleynen I, Van Steen K, Gils A, Rutgeerts P, Vermeire S, Van Assche G.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):514-521.e4. doi: 10.1016/j.cgh.2014.07.027. Epub 2014 Jul 25.

PMID:
25066841
4.

Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment.

Marits P, Landucci L, Sundin U, Davidsdottir L, Nilsson J, Befrits R, Wikström AC, Eberhardson M.

J Crohns Colitis. 2014 Aug;8(8):881-9. doi: 10.1016/j.crohns.2014.01.009. Epub 2014 Jan 31.

PMID:
24486178
5.

Ashkenazi Jewish origin protects against formation of antibodies to infliximab and therapy failure.

Ungar B, Haj-Natour O, Kopylov U, Yavzori M, Fudim E, Picard O, Loebstein R, Lahat A, Maor Y, Avidan B, Lang A, Weiss B, Chowers Y, Eliakim R, Ben-Horin S.

Medicine (Baltimore). 2015 May;94(18):e673. doi: 10.1097/MD.0000000000000673.

6.

Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.

Abraham NS, Richardson P, Castillo D, Kane SV.

Clin Gastroenterol Hepatol. 2013 Oct;11(10):1281-7. doi: 10.1016/j.cgh.2013.06.004. Epub 2013 Jun 19.

PMID:
23792295
7.

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease.

Maser EA, Villela R, Silverberg MS, Greenberg GR.

Clin Gastroenterol Hepatol. 2006 Oct;4(10):1248-54. Epub 2006 Aug 22.

PMID:
16931170
8.

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

Bortlik M, Duricova D, Malickova K, Machkova N, Bouzkova E, Hrdlicka L, Komarek A, Lukas M.

J Crohns Colitis. 2013 Oct;7(9):736-43. doi: 10.1016/j.crohns.2012.10.019. Epub 2012 Nov 29.

PMID:
23200919
9.

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

Ungar B, Chowers Y, Yavzori M, Picard O, Fudim E, Har-Noy O, Kopylov U, Eliakim R, Ben-Horin S; ABIRISK consortium.

Gut. 2014 Aug;63(8):1258-64. doi: 10.1136/gutjnl-2013-305259. Epub 2013 Sep 16.

PMID:
24041539
10.

A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.

Arias MT, Vande Casteele N, Vermeire S, de Buck van Overstraeten A, Billiet T, Baert F, Wolthuis A, Van Assche G, Noman M, Hoffman I, D'Hoore A, Gils A, Rutgeerts P, Ferrante M.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):531-8. doi: 10.1016/j.cgh.2014.07.055. Epub 2014 Aug 10.

PMID:
25117777
11.

Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remission.

Papamichael K, Vande Casteele N, Gils A, Tops S, Hauenstein S, Singh S, Princen F, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M.

Clin Gastroenterol Hepatol. 2015 Jun;13(6):1103-10. doi: 10.1016/j.cgh.2014.11.026. Epub 2014 Dec 3.

PMID:
25478919
12.

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

Ben-Horin S, Waterman M, Kopylov U, Yavzori M, Picard O, Fudim E, Awadie H, Weiss B, Chowers Y.

Clin Gastroenterol Hepatol. 2013 Apr;11(4):444-7. doi: 10.1016/j.cgh.2012.10.020. Epub 2012 Oct 24.

PMID:
23103905
13.

Concentrations of 6-thioguanine nucleotide correlate with trough levels of infliximab in patients with inflammatory bowel disease on combination therapy.

Yarur AJ, Kubiliun MJ, Czul F, Sussman DA, Quintero MA, Jain A, Drake KA, Hauenstein SI, Lockton S, Deshpande AR, Barkin JS, Singh S, Abreu MT.

Clin Gastroenterol Hepatol. 2015 Jun;13(6):1118-24.e3. doi: 10.1016/j.cgh.2014.12.026. Epub 2015 Jan 3.

PMID:
25562796
14.

Antibody response to infliximab and its impact on pharmacokinetics can be transient.

Vande Casteele N, Gils A, Singh S, Ohrmund L, Hauenstein S, Rutgeerts P, Vermeire S.

Am J Gastroenterol. 2013 Jun;108(6):962-71. doi: 10.1038/ajg.2013.12. Epub 2013 Feb 19.

PMID:
23419382
15.

Factors associated with short- and long-term outcomes of therapy for Crohn's disease.

Reinisch W, Colombel JF, Sandborn WJ, Mantzaris GJ, Kornbluth A, Adedokun OJ, Miller M, Tang KL, Rutgeerts P, Cornillie F.

Clin Gastroenterol Hepatol. 2015 Mar;13(3):539-547.e2. doi: 10.1016/j.cgh.2014.09.031. Epub 2014 Sep 19.

16.

Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease.

Steenholdt C, Palarasah Y, Bendtzen K, Teisner A, Brynskov J, Teisner B, Nielsen CH.

Aliment Pharmacol Ther. 2013 Jun;37(12):1172-83. doi: 10.1111/apt.12330. Epub 2013 May 7.

17.

Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of response.

Yarur AJ, Abreu MT.

Clin Gastroenterol Hepatol. 2014 Sep;12(9):1482-4. doi: 10.1016/j.cgh.2014.04.011. Epub 2014 Apr 13. No abstract available.

PMID:
24735794
18.

Postinduction serum infliximab trough level and decrease of C-reactive protein level are associated with durable sustained response to infliximab: a retrospective analysis of the ACCENT I trial.

Cornillie F, Hanauer SB, Diamond RH, Wang J, Tang KL, Xu Z, Rutgeerts P, Vermeire S.

Gut. 2014 Nov;63(11):1721-7. doi: 10.1136/gutjnl-2012-304094. Epub 2014 Jan 28.

19.

Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease.

Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P.

N Engl J Med. 2003 Feb 13;348(7):601-8.

20.

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis.

Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR.

Gut. 2010 Jan;59(1):49-54. doi: 10.1136/gut.2009.183095. Epub .

PMID:
19651627
Items per page

Supplemental Content

Write to the Help Desk